Resistance to chemotherapy: patient variability and cellular heterogeneity

Area of Science:

• * Cancer Research
• * Physics in Medicine
• * Computational Biology

Background:

• * Drug resistance to targeted cancer therapies presents a significant challenge to effective treatment.
• * Stochasticity, or randomness, plays a crucial role in determining patient response and tumor progression.
• * Understanding these underlying mechanisms is vital for improving cancer management strategies.

Purpose of the Study:

• * To investigate the role of stochasticity and patient variability in cancer drug resistance.
• * To analyze experimental data within a theoretical framework (Delbruck-Luria type scheme).
• * To explore the impact of local cellular environments on resistance development.

Main Methods:

• * Analysis of melanoma patient data measuring maximal response to targeted therapy.
• * Application of a Delbruck-Luria model to understand pre-existing resistant cell growth.
• * Examination of an in vitro multiple myeloma system with spatial chemotherapeutic gradients.

Main Results:

• * A Delbruck-Luria model suggests uniform maximal response unless significant patient-to-patient variation in sensitive cell response exists.
• * High variability in patient response necessitates assuming wide variations in sensitive cell therapy response.
• * In vitro experiments show rapid resistance acquisition in multiple myeloma cells within spatial gradients.

Conclusions:

• * Patient-to-patient variability in sensitive cell response is crucial for explaining observed variability in cancer drug response.
• * Local cellular environments and cell-to-cell differences contribute to rapid resistance development.
• * Stochasticity and heterogeneity are critical factors in understanding and overcoming cancer drug resistance.